Switching data build case for wider use of blockbuster Biktarvy

10 March 2020
gilead-big

California’s Gilead Sciences (Nasdaq: GILD) has announced results from a switching study of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in people who self-identified as Black or African American.

The Phase III BRAAVE 2020 trial examines the impact of switching to Biktarvy from a standard regimen of two nucleoside reverse transcriptase inhibitors (NRTIs), plus a third agent.

In a statement, Gilead said that the results show Biktarvy may “potentially be an effective and well-tolerated treatment regimen,” for patients with a history of treatment failure or pre-existing resistance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical